GSK won FDA approval Wednesday for Jideytro (zidesamtinib), its first approved lung cancer drug, for adults with locally advanced or metastatic ROS1-positive non-small-cell lung cancer after prior ROS1 kinase inhibitor treatment. In the Phase I/II ARROS-1 trial, Jideytro posted a 44% objective response rate in 117 previously treated patients, rising to 51% in the 55-patient subgroup treated with one prior ROS1 inhibitor.

Why It Matters To Oncology

• Jideytro gives clinicians a new option for ROS1-positive NSCLC after progression on prior targeted therapy, a setting with limited durable choices.

• The drug was designed to penetrate the blood-brain barrier and address ROS1 resistance mutations while maintaining selectivity, key features in a population where CNS disease is a major concern.

• At 12 months, duration of response was 69%, supporting the potential for sustained benefit beyond initial tumor shrinkage.

The Financials

• The approval could accelerate returns on GSK’s $10.6 billion Nuvalent acquisition, announced in June and closed last week.

• Jideytro was approved roughly two months ahead of its Sept. 18 PDUFA date.

• Analysts have projected nearly $2 billion in peak annual sales, though the drug enters a competitive ROS1-positive NSCLC market that includes Roche’s Rozlytrek, Bristol Myers Squibb’s Augtyro and Nuvation’s Ibtrozi.

What They're Saying

• GSK Chief Scientific Officer Tony Wood said the rapid path from development to approval reflects both the underlying science and the unmet need for additional effective, tolerable treatments in ROS1-positive lung cancer.

• Jefferies analysts have argued that improved tolerability, CNS activity and coverage of resistance mutations could help differentiate Jideytro from rivals.

What's Next

• Clinicians will watch real-world use to see whether efficacy and tolerability hold up against established ROS1 inhibitors in broader practice.

• Attention is also turning to GSK’s second Nuvalent asset, neladalkib, an ALK-selective inhibitor facing an FDA decision deadline of Nov. 27 in ALK-positive NSCLC.

• Key questions now include sequencing after prior ROS1 TKIs, uptake in patients with CNS metastases and whether Jideytro can move earlier in treatment over time.